Relevium Provides Update on Newscope Transaction


Ryan Allway

January 28th, 2020

News


MONTREAL, Jan. 28, 2020 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an update on the proposed transaction with Newscope Capital.

As announced in a letter from the CEO issued on December 19, 2019, one of the Company’s main focus for 2020 is the crystallization of the value of the existing business units. On October 29, 2019, the Company announced it had executed an LOI with Newscope Capital to unlock the value of its nutraceutical business. Concurrently, on November 8, 2019, the Company also announced it had entered into an agreement to acquire a contract manufacturing company located in Montreal, Quebec.

The purpose of this news release is to update shareholders on the progress of the proposed transaction.

APPROVAL FOR THE TRANSACTION AND UPDATED TERMS

The Company is pleased to announce it has received the support of the 2018 secured convertible noteholders (the “noteholders”) for the proposed transaction. Under the updated proposed terms for the transaction, the current notes, which are secured against all of the assets of the Company, will be exchanged for notes of Newscope Capital and the corresponding security interest will follow the shares and membership interests of BGX E-Health LLC that will be sold to Newscope Capital under the transaction resulting in the following:

  1. Newscope Capital will acquire from Relevium all of the shares and memberships interests of BGX E-Health LLC and the rights for the contract manufacturing company in Montreal, Quebec, which includes assuming the indebtedness relating to the outstanding notes with a principal and accrued interest obligation of $2.35 million, thereby reducing the purchase price being paid by Newscope Capital by an equivalent amount (see below for additional information).
  2. The term for the new notes, now an assumed liability by Newscope Capital, shall be extended to 24 months following the closing date of the transaction, bearing the same interest rate, a conversion equal to the transaction price, namely $0.50 per share, and a mechanism for early repayment subject to the concurrent financing and listing of the shares of Newscope Capital on the Canadian Securities Exchange (CSE).
  3. Without any restrictions, Relevium undertakes to escrow the shares it receives from Newscope Capital pursuant to the transaction to provide additional security to the noteholders.
  4. Relevium will remain obligated to the noteholders with non-convertible notes totalling $325,000, which is expected to be paid in instalments over four months. If Relevium closes a significant financing, it is intended that the remaining notes will become accelerated and repaid in full.

The final terms of the transaction will be reflected in the Definitive Agreement between Relevium and Newscope, which is expected to be executed imminently, and the parties intend to proceed to the formal closing of the transaction before the end of this quarter.

Relevium is now working on seeking the approval from its shareholders at the upcoming annual and special meeting of the shareholders of the Company, which is scheduled for the end of February in Montreal, Quebec. Shareholder approval is required since the interest in Bioganix E-Health LLC represents a significant asset of Relevium, however the Company views the transaction as a monetization since Relevium will hold a majority of the issued and outstanding shares of Newscope Capital following the closing.

The transaction is also subject to approval by the TSX Venture Exchange and the Canadian Securities Exchange.

UPDATED TERMS AND DEFINITIVE AGREEMENT

In view of the developments described above, the Company is also pleased to provide a summary of the updated terms of the transaction, subject to the execution of the Definitive Agreement between the parties.

Under the updated terms of the transaction, Newscope Capital will acquire all of the shares and memberships interests of BGX E-Health LLC and the rights for the contract manufacturing company in Montreal, Quebec for a total consideration of $10 million less the assumed indebtedness of $2.35 million for a net payment by Newscope Capital of $7.65 million, which is expected to be satisfied as follows:

  1. A minimum of $500,000 in cash, of which $200,000 has already been advanced by Newscope Capital to Relevium in the form of a demand promissory note ranking only behind the security granted to the noteholders.
  2. $7,150,000 in shares of Newscope, representing a total of 14.3 million shares at $0.50 per share.
  3. Relevium has agreed to a 10% holdback on the transaction through the escrow of 1,430,000 Newscope Capital shares for adjustments relating to certain revenue milestones of BGX E-Health LLC, which shall be incorporated and duly disclosed in the Definitive Agreement to be entered into between the parties.  Newscope is also assuming the performance earn-out that Relevium would have had to accept in respect of the proposed contract manufacturing company business.
  4. Newscope Capital is expected to raise a minimum of $1.5 million and up to a maximum of $5 million through a concurrent equity private placement of securities, with an issue price of no less than $0.50.  The final terms of the equity private placement are being negotiated.

Aurelio Useche, CEO of Relevium stated: “With the support from our noteholders and shareholders, we look forward to completing a successful transaction with Newscope Capital, which sets the stage for a fully integrated and focused nutraceutical company, which will not only focus on the organic growth of its business, but also execute on the acquisition of additional complimentary businesses.”

About Relevium Technologies

Relevium is a publicly traded Company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.

Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical Company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, or “would” occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.

Aurelio Useche
President and CEO

For more information about this press release: Tel: +1.888.528.8687

RELEVIUM TECHNOLOGIES INC

Email: [email protected]
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading